AAPL   399.12 (+4.02%)
MSFT   215.45 (+0.83%)
AMZN   3,328.79 (+4.02%)
CGC   17.92 (+2.87%)
BABA   260.29 (-0.28%)
TSLA   1,757.84 (+13.80%)
AMD   56.72 (+1.50%)
F   6.11 (+0.16%)
DIS   119.74 (+0.34%)
BAC   24.00 (-0.08%)
BA   175.46 (-1.67%)
AAPL   399.12 (+4.02%)
MSFT   215.45 (+0.83%)
AMZN   3,328.79 (+4.02%)
CGC   17.92 (+2.87%)
BABA   260.29 (-0.28%)
TSLA   1,757.84 (+13.80%)
AMD   56.72 (+1.50%)
F   6.11 (+0.16%)
DIS   119.74 (+0.34%)
BAC   24.00 (-0.08%)
BA   175.46 (-1.67%)
AAPL   399.12 (+4.02%)
MSFT   215.45 (+0.83%)
AMZN   3,328.79 (+4.02%)
CGC   17.92 (+2.87%)
BABA   260.29 (-0.28%)
TSLA   1,757.84 (+13.80%)
AMD   56.72 (+1.50%)
F   6.11 (+0.16%)
DIS   119.74 (+0.34%)
BAC   24.00 (-0.08%)
BA   175.46 (-1.67%)
AAPL   399.12 (+4.02%)
MSFT   215.45 (+0.83%)
AMZN   3,328.79 (+4.02%)
CGC   17.92 (+2.87%)
BABA   260.29 (-0.28%)
TSLA   1,757.84 (+13.80%)
AMD   56.72 (+1.50%)
F   6.11 (+0.16%)
DIS   119.74 (+0.34%)
BAC   24.00 (-0.08%)
BA   175.46 (-1.67%)
Log in

NASDAQ:STAASTAAR Surgical Stock Price, Forecast & News

$58.77
+0.14 (+0.24 %)
(As of 07/13/2020 11:35 AM ET)
Add
Compare
Today's Range
$58.77
Now: $58.77
$59.80
50-Day Range
$38.48
MA: $48.47
$61.62
52-Week Range
$23.20
Now: $58.77
$62.51
Volume3,362 shs
Average Volume985,179 shs
Market Capitalization$2.67 billion
P/E Ratio217.67
Dividend YieldN/A
Beta1.68
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers intraocular lenses (IOLs), including collamer material and silicone foldable IOLs, and nanoFLEX IOL that produces a clearer image, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision centers, surgical centers, hospitals, government facilities, and distributors primarily under the STAAR, EVO Visian ICL, Evolution in Visual Freedom, Visian, Collamer, CentraFLOW, AquaPORT, nanoFLEX, nanoPOINT, and Afinity trademarks. The company sells products directly through its sales representatives in the United States, Japan, Spain, Germany, Canada, the United Kingdom, and Singapore, as well as through independent distributors in China, Korea, India, and internationally. STAAR Surgical Company was founded in 1982 and is based in Monrovia, California.
Read More
STAAR Surgical logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Ophthalmic goods
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:STAA
CUSIP85231230
Phone626-303-7902

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150.18 million
Cash Flow$0.57 per share
Book Value$3.59 per share

Profitability

Net Income$14.05 million

Miscellaneous

Employees475
Market Cap$2.67 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive STAA News and Ratings via Email

Sign-up to receive the latest news and ratings for STAA and its competitors with MarketBeat's FREE daily newsletter.

STAAR Surgical (NASDAQ:STAA) Frequently Asked Questions

How has STAAR Surgical's stock been impacted by COVID-19 (Coronavirus)?

STAAR Surgical's stock was trading at $28.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, STAA shares have increased by 109.8% and is now trading at $58.77. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of STAAR Surgical?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for STAAR Surgical.

When is STAAR Surgical's next earnings date?

STAAR Surgical is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for STAAR Surgical.

How were STAAR Surgical's earnings last quarter?

STAAR Surgical (NASDAQ:STAA) issued its quarterly earnings data on Wednesday, May, 6th. The medical instruments supplier reported $0.04 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.03 by $0.01. The medical instruments supplier had revenue of $35.19 million for the quarter, compared to the consensus estimate of $34.90 million. STAAR Surgical had a return on equity of 12.52% and a net margin of 8.21%. STAAR Surgical's quarterly revenue was up 8.0% on a year-over-year basis. View STAAR Surgical's earnings history.

What price target have analysts set for STAA?

5 brokers have issued 12-month price targets for STAAR Surgical's stock. Their forecasts range from $41.00 to $70.00. On average, they anticipate STAAR Surgical's share price to reach $57.40 in the next twelve months. This suggests that the stock has a possible downside of 2.3%. View analysts' price targets for STAAR Surgical.

Has STAAR Surgical been receiving favorable news coverage?

News stories about STAA stock have trended very negative on Monday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. STAAR Surgical earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news articles about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about STAAR Surgical.

Who are some of STAAR Surgical's key competitors?

What other stocks do shareholders of STAAR Surgical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Ring Energy (REI), Ring Energy (REI), Rockwell Medical (RMTI), Sangamo Therapeutics (SGMO), AbbVie (ABBV), Advanced Micro Devices (AMD) and Amarin (AMRN).

Who are STAAR Surgical's key executives?

STAAR Surgical's management team includes the following people:
  • Ms. Caren L. Mason, CEO, Pres & Director (Age 65)
  • Ms. Deborah J. Andrews, Chief Financial Officer (Age 62)
  • Dr. Keith Holliday, Chief Technology Officer (Age 56)
  • Mr. Samuel J. Gesten, Chief Legal Officer & Corp. Sec. (Age 57)
  • Mr. Hans-Martin Blickensdoerfer, Sr. VP of Commercial Operations, Direct Markets- Europe & China (Age 54)

What is STAAR Surgical's stock symbol?

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

Who are STAAR Surgical's major shareholders?

STAAR Surgical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Defender Capital LLC. (1.22%), Envestnet Asset Management Inc. (0.06%) and TRUE Private Wealth Advisors (0.00%). Company insiders that own STAAR Surgical stock include Broadwood Partners, LP, Caren L Mason, Deborah J Andrews, Graydon C Hansen, Hans-Martin Blickensdoerfer, Jon K Hayashida, Keith Holliday, Samuel J Gesten, Scott D Barnes and William P Wall. View institutional ownership trends for STAAR Surgical.

Which institutional investors are selling STAAR Surgical stock?

STAA stock was sold by a variety of institutional investors in the last quarter, including Defender Capital LLC., and TRUE Private Wealth Advisors. Company insiders that have sold STAAR Surgical company stock in the last year include Deborah J Andrews, Graydon C Hansen, Hans-Martin Blickensdoerfer, Jon K Hayashida, Keith Holliday, Samuel J Gesten, and Scott D Barnes. View insider buying and selling activity for STAAR Surgical.

Which institutional investors are buying STAAR Surgical stock?

STAA stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for STAAR Surgical.

How do I buy shares of STAAR Surgical?

Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is STAAR Surgical's stock price today?

One share of STAA stock can currently be purchased for approximately $58.77.

How big of a company is STAAR Surgical?

STAAR Surgical has a market capitalization of $2.67 billion and generates $150.18 million in revenue each year. The medical instruments supplier earns $14.05 million in net income (profit) each year or $0.46 on an earnings per share basis. STAAR Surgical employs 475 workers across the globe.

What is STAAR Surgical's official website?

The official website for STAAR Surgical is www.staar.com.

How can I contact STAAR Surgical?

STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.